Q1 Fiscal 2024 Capital Structure Review slide image

Q1 Fiscal 2024 Capital Structure Review

INVESTMENT IN DISRUPTIVE TECHNOLOGY-BIOSYNTHESIS hyasynth 49% ownership (if convertible debt converted) of Hyasynth Biologicals Inc., a pioneer in cannabinoid science - supply agreement in place • Biosynthesis process uses patent-pending yeast strains and enzymes to produce pure cannabinoids (not synthetic) without growing cannabis plants Potential to create a scalable supply of pure cannabinoids at a fraction of the cost and time of traditional cultivation using smaller environmental footprint BIOSYNTHESIS A proprietary cannabinoid manufacturing system that can product rare cannabinoids. How it works? Biosynthesis can be used to produce cannabinoids that are identical to those produced by the plant itself. 1 Genome engineering of yeast: A group of genes for cannabinoid production are added to the yeast genome of a yeast strain, where it provides instructions to produce cannabinoid compounds. Yeast fermentation and purification: New yeast strains are grown in fermentation over a few days and pure cannabinoids are extracted at the end of the process. 3 2 The process is conducted at large scale, resulting in pure cannabinoids that can be used as ingredients in other products. ORGANIGRAM
View entire presentation